Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Resistance overhead Support Level: $164.52 Resistance Level: $171.61-$178.49 AZN has trended lower over the last month, remains below the $171.61-$178.49 resistance zone, and while the bounce from $164.52 is constructive, it still looks like stabilization rather than a confirmed reversal.
Sentiment & News
Key News Insights: ⢠Growth momentum ⢠Trial setback ⢠Investor scrutiny AstraZeneca's July 2026 news flow was mostly constructive on growth, sustainability, and institutional buying, but a sharp Wainua trial-related selloff and follow-on investigations quickly turned sentiment cautious.
AI Summary
AstraZeneca remains a high-quality grower with strong revenue, profitability, and pipeline momentum, but after the Wainua setback the stock is now priced for flawless execution, so near-term upside likely depends on regaining the 171.61â178.49 resistance zone without another clinical miss.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 2 | Jul 9 | AZN | AstraZeneca PLC | Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days. | Closed | -8.5% |
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |